Head-to-head evidence
Atozet (ezetimibe/atorvastatin) vs MK0653A, ezetimibe (+) simvastatin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
Atozet (ezetimibe/atorvastatin)
Developed by Organon
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
MK0653A, ezetimibe (+) simvastatin
Developed by Organon
NCT00092651 · Phase 3 · completed
The study was randomized and double-blind, included active comparator groups, and enrolled 1,398 participants. Its primary endpoint was the surrogate measure of change in plasma LDL-C after 12 weeks, but results and statistical significance were not posted, so the endpoint cannot be judged as met or missed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atozet (ezetimibe/atorvastatin)'s landscape · MK0653A, ezetimibe (+) simvastatin's landscape